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ABSTRACT
Clear cell carcinoma of the ovary has distinct biology and 
clinical behavior. There are significant geographical and 
racial differences in the incidence of clear cell carcinoma 
compared with other epithelial ovarian tumors. Patients 
with clear cell carcinoma are younger, tend to present at 
an early stage, and their tumors are commonly associated 
with endometriosis, which is widely accepted as a 
direct precursor of clear cell carcinoma and has been 
identified pathologically in approximately 50% of clear cell 
carcinoma cases. The most frequent and important specific 
gene alterations in clear cell carcinoma are mutations of 
AT- rich interaction domain 1A (ARID1A) (~50% of cases) 
and phosphatidylinositol-4,5- bisphosphate 3- kinase 
catalytic subunit alpha (PIK3CA) (~50% cases). More 
broadly, subgroups of clear cell carcinoma have been 
identified based on C- APOBEC (apolipoprotein B mRNA 
editing enzyme, catalytic polypeptide- like) and C- AGE 
(age- related) mutational signatures. Gene expression 
profiling shows upregulation of hepatocyte nuclear factor 
1- beta (HNF1β) and oxidative stress- related genes, 
and has identified epithelial- like and mesenchymal- like 
tumor subgroups. Although the benefit of platinum- 
based chemotherapy is not clearly defined it remains 
the mainstay of first- line therapy. Patients with early- 
stage disease have a favorable clinical outcome but the 
prognosis of patients with advanced- stage or recurrent 
disease is poor. Alternative treatment strategies are 
required to improve patient outcome and the development 
of targeted therapies based on molecular characteristics 
is a promising approach. Improved specificity of the 
histological definition of this tumor type is helping these 
efforts but, due to the rarity of clear cell carcinoma, 
international collaboration will be essential to design 
appropriately powered, large- scale clinical trials.
INTRODUCTION
Ovarian cancer is a heterogeneous disease and at least 
five types of epithelial ovarian cancer – high- grade 
serous, low- grade serous, mucinous, endometrioid, 
and clear cell carcinomas – are defined at the morpho-
logical level, before considering molecular subtypes.1 
Much of the historical evidence regarding therapeutic 
efficacy in ovarian carcinoma either identifies histo-
logical type based on poorly reproducible criteria or 
does not distinguish one type from another.2 There-
fore, much of the evidence regarding ovarian cancer 
treatment reflects the predominant histological type, 
which is high- grade serous carcinoma.2 However, it 
is now evident that clear cell carcinoma is a discrete 
entity, both biologically and clinically, and treatment 
should be specific for this type. In this review we 
consider the pathology and clinical behavior of clear 
cell carcinoma and discuss the extent to which this 
impacts its management compared with other types 
of ovarian carcinoma. We also highlight areas where 
further research is required.
EPIDEMIOLOGY
In the general population, it is estimated that 1.3% of 
women will develop ovarian cancer in their lifetime.3 
There are significant geographical and racial differ-
ences in the incidence of clear cell carcinoma, which 
is higher in Korea (10.3%), Taiwan (18.6%), and Japan 
(15%–25%)4–7 than in North America and Europe 
(1%–12%).8 9 The reasons for these differences in 
incidence are not clear, although molecular differ-
ences between tumors arising in different popula-
tions have been described; these are discussed in the 
section on molecular pathology. According to Surveil-
lance, Epidemiology, and End Results (SEER) data, 
in women living in the United States, the proportion 
of clear cell carcinoma in whites, blacks, and Asians 
with epithelial ovarian cancer was 4.8%, 3.1%, and 
11.1%, respectively.10 The median age of patients 
with clear cell carcinoma was significantly younger 
than that of serous carcinoma of the ovary (55 vs 64 
years).10 Clear cell carcinoma is often associated with 
endometriosis,11 12 and the presence of endometri-
osis has been associated with a good prognosis.13 
Although the molecular mechanisms underlying 
malignant transformation have not been elucidated 
fully, endometriosis, particularly ovarian endometri-
osis, is widely accepted as a direct precursor of endo-
metrioid and clear cell carcinomas of the ovary.14 15 
This is supported by data showing that women with 
histologically proven endometriosis have a signifi-
cantly elevated age- adjusted incidence rate ratio of 
2.29 (95% CI 1.24 to 4.20) for clear cell carcinoma16 
and by the identification of endometriosis in the final 
pathology report in 51% of cases of clear cell carci-
noma.17 The incidence of thromboembolic complica-
tions, such as deep venous thrombosis and pulmo-
nary embolism, is reported to be higher (up to 40%) in 
patients with clear cell carcinoma than in those with 
other ovarian carcinoma types,18 and is considered an 
independent poor prognostic factor.19 20
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Clear cell carcinoma tends to be diagnosed at an earlier stage 
than serous carcinoma, with 57%–81% and 19%–22%, respec-
tively, presenting at stage I or II.8 10 21 In early stage, especially 
stage IA and IC1 (rupture alone) disease, the prognosis of clear 
cell carcinoma patients is good; 5- year disease- free survival 
rates of patients with stage IA and IC1 clear cell carcinoma were 
84%–100% and 86%–89%, respectively.10 21–25 Stage IB clear cell 
carcinoma is uncommon and data on the prognosis of stage IB clear 
cell carcinoma are limited. Chan et al reported a 5year disease- 
specific survival of 56.3% for patients with stage IB clear cell carci-
noma, which was significantly lower than other histological types.10 
A longitudinal analysis reported a median disease- specific survival 
of only 10.2 months for advanced- stage (International Federation of 
Gynecology and Oncology (FIGO) III/IV) clear cell carcinoma cases, 
compared with over 4 years for the overall clear cell carcinoma 
population.26 The prognosis of patients with early- stage clear 
cell carcinoma is similar to or better than that of patients with 
serous carcinoma.10 27–29 In a review of patients who participated 
in 12 prospective randomized Gynecologic Oncology Group (GOG) 
studies, progression- free survival was significantly better in clear 
cell carcinoma than in serous carcinoma, with a trend towards 
improved overall survival in stage I and II patients (progression- free 
survival hazard ratio (HR) 0.69, 95% CI 0.50 to 0.96; overall survival 
HR 0.76, 95% CI 0.53 to 1.09)29 . In a meta- analysis, there was no 
significant difference in the HR of overall survival between clear cell 
carcinoma and serous carcinoma in stage I and II patients (HR 0.87, 
95% CI 0.75 to 1.02).30 However, in advanced stage, the prognosis 
of patients with clear cell carcinoma was remarkably poorer than 
that of patients with serous carcinoma.21 29–31 In the same review 
of data from 12 prospective randomized GOG trials, advanced- 
stage clear cell carcinoma had worse progression- free survival and 
overall survival compared with advanced- stage serous carcinoma 
(overall survival HR 1.66, 95% CI 1.43 to 1.91).29 Furthermore, in 
the meta- analysis, advanced- stage clear cell carcinoma showed a 
higher HR for death than serous carcinoma (HR 1.71, 95% CI 1.57 
to 1.86).30 This poorer outcome for patients with advanced- stage 
clear cell carcinoma has been confirmed in a study based on SEER 
data.32
Recurrence of clear cell carcinoma tends to occur at multiple 
sites, and Hogan et al reported that 38 of 61 patients with recur-
rent clear cell carcinoma (62%) had multiple- site recurrence 
involving pelvic, extrapelvic, intrathoracic, lymph node and cere-
bral/meningeal sites.33 The prognosis of patients with recurrent 
clear cell carcinoma is poorer than that of patients with recurrent 
serous carcinoma.34 . When recurrence occurs at a single site, or 
is restricted to lymph nodes, survival is longer and disease- free 
interval can be prolonged by surgery; however, this is based on 
retrospective data.33 This is consistent with the better outcome of 
patients with isolated lymph node relapse of ovarian carcinoma 
of all histotypes.35 A retrospective study compared 113 patients 
with recurrent clear cell carcinoma to 365 patients with recurrent 
serous carcinoma (type not specified) to estimate long- term clinical 
outcome. The rate of 5- year post- recurrence survival was signifi-
cantly lower in recurrent clear cell carcinoma than in recurrent 
serous carcinoma (13.2% and 18.2%, p<0.0001). On multivari-
able analysis, there was a significant difference in overall survival 
between patients with recurrent clear cell carcinoma and recurrent 
serous carcinoma (HR 2.30, 95% CI 1.72 to 3.07, p<0.0001). In 
deceased patients with clear cell carcinoma, 67.8% and 93.1% died 
within 12 and 24 months of recurrence, respectively. In contrast, in 
deceased patients with serous carcinoma, 40.7% and 73.0% died 
within 12 and 24 months of recurrence, respectively.34
DEFINITION AND MOLECULAR PATHOLOGY
Histopathological Diagnosis
The diagnostic criteria for clear cell carcinoma have been refined, 
enabling more robust and reproducible diagnosis of this tumor 
type.36–38 Typical cases have characteristic morphological features, 
including a combination of papillary, tubulocystic, and solid 
patterns, combined with clear and eosinophilic cells, and stromal 
hyalinization. The presence of background endometriosis or clear 
cell adenofibroma is also helpful in supporting the diagnosis. The 
recognition that other types of ovarian carcinoma, including high- 
grade serous carcinoma and endometrioid carcinoma, can contain 
areas with clear cell change has improved the specificity of a 
clear cell carcinoma diagnosis, which can now be made using a 
combination of morphological and immunohistochemical features 
(Figure  1). In particular, clear cell carcinoma is typically positive 
Figure 1 Histopathological features of clear cell carcinoma. 
Hematoxylin and eosin (H&E) staining shows (A) papillary 
and (B) tubulocystic patterns formed by malignant 
cells with variably clear and eosinophilic cytoplasm. 
Immunohistochemistry shows a (C) Wilms tumor 1 (WT1)- 
negative, (D) p53 wild- type, (E) estrogen receptor (ER)- 
negative, and (F) napsin A- positive immunoprofile.
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for napsin A and hepatocyte nuclear factor 1- beta (HNF1β), and 
negative for Wilms tumor 1 (WT1) and estrogen receptor (ER); 
high- grade serous carcinoma shows the inverse immunoprofile, 
and endometrioid carcinoma is negative for napsin A and WT1, and 
positive for ER.36–38
Molecular Analyses
A number of sequencing analyses have been performed in clear cell 
carcinoma (Table 1). These results and gene alterations previously 
reported are summarized in Table 2. The most frequent gene altera-
tions in clear cell carcinoma are in the AT- rich interaction domain 1A 
(ARID1A)39–44 and phosphatidylinositol-4,5- bisphosphate 3- kinase 
catalytic subunit α (PIK3CA)39 41–46 genes (both occurring in about 
50% of cases).
SWI/SNF Chromatin Remodeling Complex
ARID1A encodes ARID1A/BAF250A, which is a key component of 
the switch/sucrose nonfermentable ATP- dependent (SWI/SNF) 
chromatin remodeling complex that regulates gene expression 
targeting multiple tumorigenesis pathways47 . In addition to ARID1A 
mutation, mutations of ARID1B (6%–18%)41 42 48 and SWI/SNF 
related, matrix associated, actin dependent regulator of chromatin, 
subfamily a member 4 (SMARCA4) (5%–18%)41 49 affect the SWI/
SNF chromatin remodeling complex.
PI3K/AKT/mTOR Pathway
PIK3CA encodes the catalytic subunit p110α of phosphatidy-
linositol 3- kinase (PI3K). Somatic mutation of PIK3CA increases 
PI3K activity and activates the downstream AK strain trans-
forming (AKT) pathway50 . In addition to PIK3CA mutation, muta-
tions of phosphoinositide-3- kinase regulatory subunit 1 (PIK3R1) 
(7%–10%),41–43 48 51 mutations of phosphatase and tensin homolog 
(PTEN) (2%–13%),41–44 49 and amplification of AKT serine/threonine 
kinase 2 (AKT2) (8%–26.6%)41 44 have been reported as genetic 
changes that affect the PI3K/AKT pathway.50
Combined SWI/SNF and PI3K/AKT/mTOR Alterations
An association between loss of ARID1A expression and activa-
tion of the PI3K/AKT pathway in clear cell carcinoma has been 
reported.52 53 Among 17 clear cell carcinoma cases with PIK3CA 
mutation, 71% were found in those with loss of ARID1A protein 
expression.52 Another study showed that the loss of ARID1A 
expression was more frequent in clear cell carcinoma cases with 
an activated PI3K/AKT pathway (PIK3CA mutations or loss of PTEN 
expression) (54%) than those without activation of the PI3K/AKT 
pathway (30%) (p=0.046).53 According to studies using next- 
generation sequencing, ARID1A and PIK3CA variants co- occurred 
in 20%–56% clear cell carcinoma cases,41 44 54 55 and 82% of 
tumors with activation of the PI3K/AKT pathway were observed in 
tumors with mutations of the SWI/SNF subunit genes.41 ARID1A 
and PIK3CA mutations are likely to occur at an early stage in the 
development of clear cell carcinoma, as they are also detected in 
endometriosis, which is considered to be a precursor lesion of clear 
cell carcinoma.14 In a genetically engineered mouse model, loss 
of ARID1A and activating mutations of PIK3CA were sufficient to 
Table 1 Next- generation sequencing studies
Author Year n Tumor site Stage Sample Sequence Reference
Friedlander 2016 105 N/A N/A FFPE 46- gene panel 45
Wang 2017 35 Primary N/A Frozen tissue Whole- genome 
sequencing
43
Maru 2017 18 Primary I/II 15 (83.3%)
III/IV 3 (16.7%)
FFPE 409- gene panel 49
Elvin 2017 125 Primary (45.6%) 
and metastatic 
(54.4%)
N/A FFPE FoundationOne 315- gene 
panel
55
Arildsen 2017 10 Primary N/A FFPE 60- gene panel 54
Itamochi 2017 55 Primary I/II 33 (60%)
III/IV 22 (40%)
Frozen tissue Whole- genome 
sequencing
41
Murakami 2017 39 Primary N/A Frozen tissue Whole- exome sequencing 42
Shibuya 2017 48 Primary I/II 29 (60.4%)
III/IV 19 (39.6%)
FFPE Whole- exome sequencing 48
Kim 2018 15 Primary I/II 11 (73.3%)
III/IV 4 (26.7%)
Frozen tissue Whole- exome sequencing 44
Caumanns 2018 124 Primary N/A Frozen tissue Kinome sequencing
518 kinases, 13 
diglyceride kinases, 
18 PI3K domain and 
regulatory component 
genes, and 48 cancer- 
related genes
127
Takenaka 2019 68 Primary I/II 19 (27.9%)
III/IV 49 72.0%)
FFPE 103- gene panel 51
FFPE, formalin- fixed paraffin- embedded tissue; N/A, not available.
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generate tumors that phenotypically and molecularly resembled 
human clear cell carcinoma.56
Mitogen-Activated Protein Kinase (MAPK) Pathway
Genetic changes in the mitogen- activated protein kinases (MAPK) 
pathway, such as mutation of protein phosphatase 2 scaffold 
subunit alpha (PPP2R1A) (4.1%–20%)39 42–44 57 and the KRAS 
proto- oncogene, GTPase (KRAS) (4.7%–20%);39 41–45 54 55 mutation 
and amplification of erb- b2 receptor tyrosine kinase 2 (ERBB2) 
(4%–13%);41 44 49 54 55 and amplification of the MET proto- oncogene 
(MET) (24%–37%)58 59 have been reported.
TP53, Homologous Recombination Deficiency, and Telomerase
Unlike high- grade serous carcinoma, clear cell carcinomas usually 
express wild- type p53 protein and have a lower frequency of BRCA1 
and BRCA2 mutations;41 44 BRCA mutations have been identified in 
approximately 6% (1% germline, 5% somatic) of cases, and muta-
tions in homologous recombination pathway genes in up to 28% 
overall.60 The frequency of TP53 mutations in clear cell carcinoma 
has been reported to be approximately 8.5%–21.6%.43–45 49 55 It 
is possible, however, that some of the TP53 and BRCA1- mutated 
carcinomas categorized as clear cell carcinoma in these cohorts 
are high- grade serous carcinomas with areas of clear cell change. 
Clear cell carcinoma has a higher frequency of telomerase reverse 
transcriptase (TERT) promoter mutation (5.7%–16.0%) than other 
histological types of epithelial ovarian cancer.61 62 TERT promoter 
mutation does not appear to be an early event in the carcinogenesis 
of clear cell carcinoma, as it was not observed in endometriosis 
progressing to clear cell carcinoma.61
Mutational Signatures
Two major subgroups of clear cell carcinoma have been identified 
based on mutational signatures: C- APOBEC, characterized by an 
apolipoprotein B mRNA editing enzyme, catalytic polypeptide- like 
(APOBEC) mutation signature (26%), and C- AGE, characterized 
by an age- related (AGE) mutation signature (40%).43 Consistent 
with this, another study reported an APOBEC signature in 18% of 
clear cell carcinoma.48 The APOBEC mutational process has been 
proposed as a therapeutic target to prevent ongoing clonal evolu-
tion in disease progression.63 A multi- region sequencing study 
showed APOBEC- mediated kataegis to be an early event in clear 
cell carcinoma development, with APOBEC3B expression associ-
ated with infiltration by cytotoxic T cells and favorable outcome. 
Moreover, in another study, APOBEC3B overexpression was shown 
to associate with improved clinical outcome in clear cell carcinoma 
and to have a potential role in predicting response to platinum- 
based chemotherapy.64
Copy-Number Alterations
The total number of copy- number alterations in clear cell carci-
noma is similar to that in low- grade serous carcinoma,65 and much 
lower than in high- grade serous carcinoma.65 66 Conversely, the 
ratio of whole- arm copy- number alterations in clear cell carcinoma 
was significantly higher than in serous carcinoma.66 Whole- arm 
Table 2 Summary of critical genetic changes in ovarian clear cell carcinoma
Gene Changes Pathways affected References
ARID1A Mutation in approximately 50% SWI/SNF chromatin 
remodeling complex
39–44 48 51 54 55 127 128
ARID1B Mutation in 6%–18% SWI/SNF chromatin 
remodeling complex
41 42 48 51
SMARCA4 Mutation in 5%–18% SWI/SNF chromatin 
remodeling complex
41 48 49
PIK3CA Mutation in approximately 50% PI3K/AKT 39 41–46 48 51 54 55 127 128
PIK3R1 Mutation 7%–10% PI3K/AKT 41–43 48 51 127 128
AKT2 Amplification in 8%–26% PI3K/AKT 41 44 58 128
PTEN Mutation in 2%–13% PI3K/AKT 41–44 49 127 128
KRAS Mutation in 4.7%–20% MAPK 39 41–45 48 51 54 55 127 128
PPP2R1A Mutation in 4.1%–20% MAPK 39 42–44 48 51 57 128
ERBB2 Mutation and amplification in 
2%–13%
MAPK 41 44 49 54 55 128
MET Amplification in 24%–37% MAPK 58 59
TP53 Mutation in 8.5%–21.6% DNA repair 43–45 49 51 55 127–129
TERT promoter Mutation in 5%–16% TERT 61 62 130
ZNF217 Amplification in 20%–36% ZNF217 65 68 69
Based on Mabuchi et al.131
AKT2, AKT serine/threonine kinase 2; ARID1A, AT- rich interactive domain 1A; ARID1B, AT- rich interactive domain 1B; ERBB2, erb- b2 
receptor tyrosine kinase 2; GTPase, PPP2R1A, protein phosphatase 2 scaffold subunit A; KRAS, KRAS proto- oncogene; MET, MET proto- 
oncogene, receptor tyrosine kinase; PI3K, phosphatidylinositol 3- kinase; PIK3CA, phosphatidylinositol-4,5- bisphosphate 3- kinase catalytic 
subunit alpha; PIK3R1, phosphoinositide-3- kinase regulatory subunit 1; PTEN, phosphatase and tensin homolog; SMARCA4, SWI/SNF- 
related, matrix- associated, actin- dependent regulator of chromatin, subfamily A, member 4; SWI/SNF, switch/sucrose non- fermentable; 
TERT, telomerase reverse transcriptase; ZNF217, zinc finger protein 217.
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copy- number alterations at 8q in clear cell carcinoma were also 
reported in other studies.42 67 The most remarkable region with 
copy- number gain in clear cell carcinoma is at chr20q13.2, which 
includes a potential oncogene, zinc finger protein 217 (ZNF217), 
at a frequency of 20%–36%.65 68 69 ZNF217 was amplified signif-
icantly more frequently in Japanese (62%) than in Korean (7%) or 
German (25%) clear cell carcinoma,67 and high- level amplification 
of ZNF217 was identified in C- APOBEC (33%) and C- AGE (57%) 
tumors.43 Moreover, ZNF217 amplification in clear cell carcinoma 
correlated significantly with shorter progression- free survival (HR 
2.6, 95% CI 1.1 to 6.1, p=0.339) and overall survival (HR 3.5, 
95% CI 1.1 to 10.6, p=0.031).68 The association between ZNF217 
and SWI/SNF is controversial. Loss of ARID1A expression has been 
reported to be coincident with PI3K- AKT pathway activation and/
or ZNF217 amplification.53 Conversely, in another study, the cases 
positive for all SWI/SNF subunits demonstrated significantly greater 
DNA copy- number alterations, such as amplification of chromo-
somes 20q.13.2- 20q13.33 (including ZNF217) and 8q.24.3, and 
deletion of chromosomes 13q12.11- 13q14.3 (including RB1), 
17p13.2–17 p13.1 (including TP53), and 19p13.2–19 p13.12.70
Transcriptomic Analyses
Previous microarray analyses have identified a clear cell carcinoma 
expression profile that is distinct from other histological types of 
ovarian carcinoma.66 71 72 HNF1β and oxidative stress- related genes 
are upregulated in clear cell carcinoma.73 74 Microarray analysis 
classified clear cell carcinoma into three clusters, and co- existent 
alterations of PIK3CA and ARID1A were commonly observed in two 
of these (7/11, 64%) but not in the third (0/10, 0%; p<0.01). Being 
in the cluster without co- existent PIKCA and ARID1A alteration was 
an independent favorable prognostic factor.66 Unsupervised gene 
expression analysis of clear cell carcinoma has identified two gene 
transcriptomic subtypes associated with differential outcome, 
termed epithelial- and mesenchymal- like.75 The epithelial- like 
subgroup, which had a high frequency of SWI/SNF complex muta-
tions, was associated with early stage at diagnosis and favorable 
outcome, while the mesenchymal- like group was enriched for 
advanced- stage disease at diagnosis and overall poor prognosis.
CLINICAL ASPECTS
Diagnosis
As described above, the morphological features of clear cell carci-
noma are often typical and diagnostic; and the addition of immuno-
histochemistry for WT1, p53, napsin A, and HNF1β helps to ensure 
diagnostic specificity by allowing the exclusion of, in particular, 
high- grade serous carcinoma with clear cells.36–38 70 It is important 
that clear cell carcinoma is defined robustly both in clinical practice 
and in molecular and clinical studies to ensure that patients are 
managed appropriately, and therapeutic responses and outcomes 
are accurately determined.
Surgery
Tumor stage is an important determinant of outcome and is crucial 
for clinical management. Lymphadenectomy is necessary to deter-
mine the precise stage because the rate of lymph node metas-
tasis has been reported to be 4.5%–14.4% in pT1 (tumor limited to 
ovaries (one or both)) or pT2 (tumor involving one or both ovaries 
with pelvic extension) clear cell carcinoma.22 76–78 In the Multicentre 
Italian Trials in Ovarian Cancer (MITO-9) retrospective study, disease- 
free survival was longer in patients undergoing lymphadenectomy 
at surgery, both in early- stage (p=0.026) and in advanced- stage 
(p=0.004) disease. Lymphadenectomy was independently associ-
ated with longer overall survival (HR 0.15, 95% CI 0.04 to 0.54) 
in multivariate analysis,79 although stage shift is clearly a possible 
confounding factor in this study. Other studies have failed to show 
the therapeutic benefit of lymphadenectomy for early- stage clear 
cell carcinoma23 76 78 and further studies are required to determine 
the impact of lymphadenectomy in this context.
Although it has been reported that residual disease after cytore-
ductive surgery is a strong predictor of survival in advanced- stage 
epithelial ovarian cancer, the proportion of clear cell carcinomas 
Figure 2 National Comprehensive Cancer Network (NCCN) guidelines version 1.2020 for clear cell carcinoma of the ovary.87 
IP, intraperitoneal; IV, intravenous.
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in these reports is low (3.3%–4.8%).31 80–82 There are, however, a 
few reports that examine an association between residual tumor 
and prognosis in clear cell carcinoma. Takano et al performed a 
retrospective analysis to evaluate the clinical characteristics and 
prognostic factors in the 254 patients with clear cell carcinoma of 
the ovary. There was no significant prognostic difference between 
patients with residual tumor diameter <1 cm and those with 
residual tumor diameter >1 cm (p=0.40). Patients with no residual 
tumor had significantly better progression- free survival than those 
with residual tumor <1 cm (p=0.04) or those with residual tumor 
diameter >1 cm (p<0.01), and only residual tumor diameter was 
an independent prognostic factor in advanced- stage clear cell 
carcinoma (p=0.02).22 Furthermore, Melamed et al conducted a 
retrospective cohort study to quantify the magnitude of associa-
tions between residual disease status and all- cause mortality by 
histological type using data from the National Cancer Database of 
America. Overall survival differed significantly according to residual 
disease status not only in patients with high- grade serous carci-
noma but also in those with clear cell carcinoma and, while not 
statistically significantly different, the survival benefit associated 
with cytoreduction to no residual disease was greater in clear cell 
carcinoma (HR 0.39, 95% CI 0.22 to 0.69) than in high- grade serous 
carcinoma (HR 0.58, 95% CI 0.49 to 0.68).83 Surgery to achieve 
no residual tumor may be necessary to improve the prognosis in 
advanced- stage clear cell carcinoma.
As clear cell carcinoma is found at early stage and at a younger 
age, fertility sparing is an important consideration in clinical prac-
tice. According to a summary of studies on fertility- sparing surgery 
in stage I clear cell carcinoma, there was no difference in the recur-
rence rate between patients with clear cell carcinoma and non- 
clear cell carcinoma (7/53, 13.2% and 41/377, 10.9%; p=0.61).84 
However, in another report, the recurrence rate of stage IC clear 
cell carcinoma patients who underwent fertility- sparing surgery 
was 22.5% (7/31).85 The role for fertility- sparing surgery in stage 
1B is unclear from existing data. Therefore, fertility- sparing surgery 
may be an option at least for patients with stage IA clear cell carci-
noma when adequate staging is conducted. A recent systematic 
review supports this conclusion, identifying that fertility sparing 
surgery is not associated with worse survival in patients with stage 
I disease.86
Chemotherapy
Current National Comprehensive Cancer Network (NCCN) guidelines 
for the management of clear cell carcinoma are summarized in 
Figure 2.87 Although previous NCCN guidelines recommended adju-
vant chemotherapy for clear cell carcinoma regardless of disease 
stage,88 current European Society for Medical Oncology- European 
Society of Gynaecological Oncology (ESMO- ESGO) consensus 
conference recommendations on ovarian cancer indicate that the 
benefit of adjuvant chemotherapy is uncertain for patients with 
stage IA, IB, and IC1 clear cell carcinoma, and no adjuvant chemo-
therapy is recommended for patients with stage IA, IB, and IC1 
clear cell carcinoma with complete surgical staging (Figure  3).89 
The current NCCN ovarian cancer guidelines also state that obser-
vation is an option for patients with IA clear cell carcinoma who 
have undergone complete surgical staging (Figure 2).87 The subset 
analysis in the ACTION study showed similar progression- free 
survival for patients with stage I- IIA clear cell carcinoma with or 
without adjuvant chemotherapy,90 and two retrospective analyses 
reported no benefit for adjuvant chemotherapy after complete 
surgical staging for stage IA- B clear cell carcinoma.91 92 Further-
more, a large- scale study based on SEER data revealed that there 
was no significant difference in 5- year overall survival between the 
patients with stage I clear cell carcinoma who received adjuvant 
chemotherapy (85%) and those who did not (83%) (p=0.43). This 
was also true for substage IC clear cell carcinoma, where there 
was no significant difference in 5- year overall survival between 
the patients who received adjuvant chemotherapy (83%) and those 
who did not (80%) (p=0.62).93 However, a systematic review and 
meta- analysis identified that adjuvant chemotherapy correlated 
with improved overall survival in patients with stage IC (odds ratio 
(OR) 0.70, 95% CI 0.52 to 0.93) but not stage IA or IB disease.94
A study of 210 patients showed that there was no impact of 
three versus six cycles of chemotherapy on overall survival in early- 
stage clear cell carcinoma.95 Further studies of early- stage disease 
are required to determine which stages of disease benefit from 
chemotherapy and how many cycles of adjuvant chemotherapy are 
appropriate. At present, the Japanese Gynecologic Oncology Group 
(JGOG) is performing a randomized phase III trial to evaluate the 
necessity of adjuvant chemotherapy in stage I epithelial ovarian 
cancer (stage IA/IB clear cell carcinoma or grade 2/3 other histolog-
ical type and stage IC1 with all grades and histological types) after 
comprehensive staging surgery (JGOG3020, UMIN000008481). It 
Figure 3 Adjuvant chemotherapy for patients with early- stage clear cell ovarian cancer (stage I- IIA). From European Society 
for Medical Oncology- European Society of Gynaecological Oncology (ESMO- ESGO) consensus conference recommendations 
on ovarian cancer.89 aNo adjuvant chemotherapy should be considered only for patients with complete surgical staging.
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is hoped that this trial will shed more light on the role of chemo-
therapy in stage IA/IC1 clear cell carcinoma.
In first- line chemotherapy for clear cell carcinoma, the response 
rate to a combination of paclitaxel plus platinum, which is stan-
dard therapy for ovarian carcinoma, is thought to be higher 
(22%–56%) than that of other platinum- based chemotherapy 
(11%–27%).21 22 96–99 However, the addition of taxane was not an 
independent prognostic factor in the MITO-9 study,79 and there was 
no survival benefit in advanced- stage clear cell carcinoma between 
patients treated with paclitaxel plus platinum compared with those 
treated with platinum monotherapy in a large Japanese study.22 
A randomized phase III study of paclitaxel and carboplatin versus 
dose- dense paclitaxel and carboplatin as a first- line treatment 
for stage II- IV epithelial ovarian cancer showed that dose- dense 
paclitaxel and carboplatin offers better survival than paclitaxel and 
carboplatin in ovarian cancers unselected for histological type.100 
However, in subgroup analysis of this study, there was no signifi-
cant survival benefit in patients with clear cell or mucinous tumors 
between treatment groups.100 Conversely, combination therapy 
with irinotecan hydrochloride and cisplatin has been reported to be 
effective as first- line and second- line chemotherapy for clear cell 
carcinoma.101 102
A randomized phase II study (JGOG3014) to compare combina-
tion therapy with irinotecan hydrochloride and cisplatin and pacli-
taxel/carboplatin revealed that completion rates of six cycles and 
5- year progression- free survival were similar in both arms.103 A 
subsequent randomized phase III study of combination therapy with 
irinotecan hydrochloride and cisplatin versus paclitaxel/carboplatin 
as first- line treatment for clear cell carcinoma was conducted by 
the JGOG in collaboration with the Gynecologic Cancer Intergroup 
(GCIG; JGOG3017/GCIG Trial). However, there was no significant 
survival benefit with combination therapy with irinotecan hydro-
chloride and cisplatin; 2- year progression- free survival rates were 
73.0% in the combination therapy with irinotecan hydrochloride 
and cisplatin group and 77.6% in the paclitaxel/carboplatin group 
(HR 1.17, 95% CI 0.87 to 1.58).104
In second- line or salvage chemotherapy, the response rate 
for recurrent or refractory clear cell carcinoma is extremely 
Table 3 Clinical trials of clear cell carcinoma using molecular targeted therapy
Study title Status Conditions Interventions Phase Target
ClinicalTrials.gov 
identifier
GOG-0268 Completed Newly 
diagnosed stage 
III or IV OCCC
Temsirolimus,
carboplatin, and 
paclitaxel
II mTOR NCT01196429
GOG-0254 Completed Persistent or 
recurrent OCCC
Sunitinib II PDGFRs and 
VEGFRs
NCT00979992
ENMD-2076- OCC Completed Persistent or 
recurrent OCCC
ENMD-2076 II AURKA, 
VEGFRs, 
FGFRs,
Flt3, and 
c- kit
NCT01914510
NRG- GY001 Completed Persistent or 
recurrent OCCC
Cabozantinib II MET, RET, 
VEGFR2, and 
AXL
NCT02315430
GOG-0283 Active, not 
recruiting
Persisent or 
recurrent OCCC 
or endometrial 
CCC
Dasatinib II bcr- abl, c- kit, 
and PDGF
NCT02059265
NiCCC Recruiting Persistent or 
recurrent OCCC 
and endometrial 
CCC
Nintendanib II FGFRs, 
PDGFRs, and 
VEGFRs
NCT02866370
MOCCA Recruiting Persistent or 
recurrent OCCC
Durvalumab II PD- L1 NCT03405454
BrUOG 354 Recruiting Persistent or 
recurrent OCCC 
or extra- renal 
origin CCC
Nivolumab ± 
ipilimumab
II PD-1, CTLA4 NCT03355976
NRG- GY016 Suspended Persistent or 
recurrent OCCC
Pembrolozimab and 
epacadostat
II PD-1 and 
IDO1
NCT03602586
AURKA, aurora kinase A; CCC, clear cell carcinoma; CTLA4, cytotoxic T- lymphocyte- associated protein 4; FGFR, fibroblast growth factor 
receptor; Flt3, FMS- like tyrosine kinase; IDO1, idoleamine 2,3- dioxygenase-1; MET, MET proto- oncogene, receptor tyrosine kinase; mTOR, 
mammalian target of rapamycin; OCCC, ovarian clear cell carcinoma; PD-1, programmed cell death 1; PDGF, platelet- derived growth factor; 
PDGFR, platelet- derived growth factor receptor; PD- L1, programmed cell death 1 ligand; RET, RET proto- oncogene, receptor tyrosine 
kinase; VEGFR, vascular endothelial growth factor receptor.
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low.96 97 105–108 In a large- scale study of platinum- sensitive relapsed 
ovarian carcinoma, including all histological types, the response 
rates of patients treated with paclitaxel plus platinum chemotherapy 
and those with other platinum- based chemotherapy were 66% and 
54%, respectively.109 However, even in patients with ‘platinum- 
sensitive’ relapsed clear cell carcinoma, the response rate was 
lower than 10%.105 106 In a retrospective study of 75 patients with 
recurrent or refractory clear cell carcinoma, the median overall 
survival of patients after platinum- sensitive or platinum- resistant 
relapse were 16 months and 7 months, respectively (p=0.04).106 
Chemotherapy for recurrent or refractory clear cell carcinoma 
therefore has only small benefit, especially in platinum- resistant 
relapse.
Radiotherapy
Adjuvant radiotherapy may improve the prognosis of early- stage 
clear cell carcinoma. In a retrospective analysis of stage IC, II, and 
III clear cell carcinoma to compare chemotherapy (cyclophospha-
mide, adriamycin, and cisplatin) and whole abdominal radiotherapy, 
overall survival and disease- free survival were significantly supe-
rior in the whole abdominal radiotherapy group to those in the 
chemotherapy group.110 Furthermore, a large- scale retrospective 
analysis of 241 patients with stage I and II clear cell carcinoma 
to compare adjuvant chemotherapy (three- cycle paclitaxel/carbo-
platin) followed by radiation (22.5 Gy to pelvis followed by 22.5 Gy 
to the whole abdomen) and chemotherapy (six- cycle paclitaxel/
carboplatin) only, there was a significant improvement in disease- 
free survival by 20% at 5 years within stage IC (all IC patients 
except those who were IC by virtue of rupture alone) and stage II.25 
Conversely, in a more recent retrospective study of 163 patients 
with stage I and II clear cell carcinoma, adjuvant radiotherapy was 
not significantly associated with increased progression- free or 
overall survival either in the whole group or even in the high- risk 
group (stage IC2, IC3, and II).111 The latter study was more likely to 
be subject to selection bias than the former as, in the former study, 
the decision to treat with chemo- radiotherapy or chemotherapy 
alone was based on service factors rather than patient factors. 
Further research is needed to determine the benefit of radiotherapy 
in early- stage clear cell carcinoma.
Radiotherapy may have a role in the treatment of patients with 
locoregionally recurrent clear cell carcinoma.112 113 One retrospec-
tive study of involved- field radiation therapy found higher 5- year 
overall survival (88% vs 37%, p=0.05) and disease- free survival 
(75% vs 20%, p=0.01) in eight patients with clear cell carcinoma 
compared with other histological types.114
Targeted Therapy
Some agents targeting angiogenesis (bevacizumab, sunitinib, 
nintendanib), the PI3K/AKT/mTOR pathway (temusirolimus), 
immune checkpoints (nivolumab, durvalumab), loss of BAF250a 
(dasatinib), Aurora A (ENMD-2076), and MET (cabozantanib) are 
currently being evaluated in clinical trials, either as monotherapy or 
in combination with other targeted/cytotoxic agents (Table 3).
Bevacizumab was the first targeted therapy to receive the 
approval of the European Medicine Agency for the treatment of 
epithelial ovarian cancer. ICON7, a phase III randomized study, 
assessed bevacizumab combined with carboplatin and paclitaxel in 
the upfront setting compared with carboplatin and paclitaxel alone. 
This study included patients with stage I or IIA clear cell carcinoma 
and no benefit of bevacizumab was reported for clear cell carci-
noma in a subgroup analysis,115 although this analysis was very 
underpowered and cannot be taken as evidence for absence of an 
effect of bevacizumab in clear cell ovarian carcinoma. The vascular 
endothelial growth factor receptor (VEGFR) inhibitor sunitinib 
demonstrated minimal activity in a phase II trial of patients with 
recurrent clear cell carcinoma as the second- or third- line treat-
ment, with a response rate of 6.7%.116
Temsirolimus, an inhibitor of mammalian target of rapamycin 
(mTOR), was evaluated in a phase II trial in combination with carbo-
platin and paclitaxel as first- line therapy in the treatment of stage 
III- IV clear cell carcinoma of the ovary. This regimen did not statis-
tically significantly increase progression- free survival compared 
with historical control.117 In a study of nivolumab, an immune 
checkpoint inhibitor that blocks programmed cell death 1 (PD-1), 
Table 4 Possible individualized investigational approaches to the treatment of metastatic or recurrent clear cell ovarian 
cancer.
Molecular subgroup Target Possible agent(s) Additional comments
ARID1A mutant tumors DDR pathway ATR inhibitors (±PARP inhibitors)
Histone deacetylase HDAC inhibitors   
Zeste homolog 2 EZH2 inhibitor   
PI3K/AKT/mTOR activated PI3K/AKT/mTOR pathway PI3K/mTOR/TORC inhibitors   
MAPK pathway activated MAPK pathway RAS/RAF/MEK inhibitors Inhibitor choice mutation- 
dependent
Mismatch repair deficient PD1/PD- L1 PD1/PD- L1 inhibitors May require to be part of 
basket study
Mesenchymal- type gene 
expression profile
Angiogenic pathways VEGF monoclonal antibodies and 
VEGFR tyrosine kinase inhibitors
  
ATR, ataxia telangiectasia and Rad3- related protein; DDR, DNA damage response; EZH2, Zeste homolog 2; HDAC, histone deacetylase; 
MAPK, mitogen- activated protein kinase; mTOR, mammalian target of rapamycin; PARP, poly- ADP ribose polymerase; PD1, programmed 
cell death protein 1; PD- L1, programmed death ligand 1; TORC, mammalian target of rapamycin complex; VEGF, vascular endothelial growth 
factor; VEGFR, vascular endothelial growth factor receptor.
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for platinum- resistant ovarian carcinoma, one of two patients with 
clear cell carcinoma exhibited complete response and, in a study of 
avelumab for recurrent/refractory ovarian carcinoma, both patients 
with clear cell carcinoma exhibited partial response.118 119 Immune 
checkpoint inhibitors may represent a new treatment option for 
clear cell carcinoma, and clinical trials using these are ongoing.
ENMD-2076, an oral multitarget kinase selective against Aurora 
A and VEGFR, was evaluated for its activity in patients with recur-
rent ovarian clear cell carcinoma in a phase II study. The overall 
6- month progression- free survival rate was 22% and did not 
meet the preset threshold for efficacy.120 Besides these agents, 
it has been reported that a histone deacetylase (HDAC) inhibitor 
and an enhancer of zeste homologue 2 (EZH2) inhibitor selectively 
suppressed the growth of ARID1A- mutated cells in vitro and in 
vivo,121 122 and these drugs are expected to be introduced into 
clinical trials. In a small study, high HDAC6 expression correlated 
with poor prognosis in clear cell carcinoma with ARID1A loss, and 
also with programmed death- ligand 1 (PD- L1) expression.123 This 
is consistent with the demonstration that HDAC6 inhibition can 
synergize with anti- PD- L1 therapy in a mouse model, raising the 
possibility that this combination may represent a novel therapeutic 
strategy.124
In early work, prolyl hydroxylase domain- containing protein 
2 (PHD2), encoded by EGLN1, has been identified as a potential 
hypoxia- inducible factor 1α (HIF1A)- dependent therapeutic target 
in clear cell carcinoma;125 and screening of ARID1A- deficient cells 
has suggested that gemcitabine may be an effective therapeutic 
option in ARID1A- deficient tumors.126
Post-Treatment Surveillance
Current NCCN guidelines do not recommend clear cell carcinoma- 
specific post- treatment surveillance;87 patients are followed up 
in the same way as patients with other histological tumor types. 
However, the ESMO- ESGO consensus conference recommenda-
tions on ovarian cancer indicate that CA125 is not a reliable marker 
in epithelial ovarian carcinoma types other than high- grade serous 
carcinoma.89
Future Directions
The improved definition of ovarian clear cell carcinoma, and 
greater understanding of its molecular characteristics, provide 
opportunities to develop alternative treatment strategies with the 
aim of improving survival, particularly of patients with advanced- 
stage or recurrent disease. Possible individualized investigational 
approaches based on tumor biology are suggested in Table 4. Due 
to the rarity of clear cell carcinoma, international collaboration will 
be essential to power large- scale clinical trials required to answer 
the many remaining questions regarding the optimal treatment of 
this disease. Accurate diagnosis, particularly the exclusion of clear 
cell carcinoma mimics such as high- grade serous carcinoma with 
clear cells, will be crucial for these trials to produce reliable find-
ings. Specific areas that merit further investigation include the rela-
tionship between mismatch repair (MMR) deficiency and response 
to immune checkpoint inhibitors, the prevalence of BRCA mutation 
and its relationship to poly- ADP ribose polymerase (PARP) inhibitor 
response, and the development of novel therapies based on tumor 
biology.
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